Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.
Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
Advertisement
Articles by Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Advertisement
Latest Updated Articles
ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and LeukemiaPublished: December 15th 2025 | Updated:
All-Oral Revumenib Regimen May Show Advantage in Newly Diagnosed AMLPublished: December 7th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel Vaccine Combo Shows Responses in Recurrent Epithelial Ovarian Cancer
2
Relacorilant/Nab-Paclitaxel Meets OS End Point in Platinum-Resistant Ovarian Cancer
3
Firmonertinib Demonstrates Promise in EGFR+ Advanced/Metastatic NSCLC
4
Sacituzumab Govitecan Combo Reduces Progression, Death By 35% in Metastatic TNBC
5